Back Menu
id опорной категории = 2
id текущей категории = 1
id родительской категории = 1

Genetico Laboratory Examined over 28,000 Embryos for Chromosomal Abnormalities

At the end of January 2021, the laboratory of the Genetico® Center (GENETICO LLC, HSCI’s subsidiary, a Skolkovo resident) received a 10,000 application for preimplantation genetic testing for chromosomal abnormalities (PGT-A). Currently, the laboratory has already examined more than 28,000 embryos.

Genetico® laboratory develops and implements Embryotest PGT-A. This is a check of embryos for chromosomal abnormalities during IVF before transferring the embryo into the uterine cavity. In addition, Genetico® Center conducts a study of the frequency of occurrence of certain types of chromosomal abnormalities in order to assess their significance for the problem of infertility and the prevention of genetic diseases.

According to Elizaveta Musatova, the Medical Director of Genetico® Center: “Among 28,000 samples analyzed, the proportion of embryos with chromosomal abnormalities is 56%. The average age of our patients is 37 years. The frequency of occurrence of chromosomal abnormalities is influenced by the age factor, and at a woman’s age of 40 and older, the proportion of embryos with chromosomal abnormalities reaches 78%. Therefore, it is extremely important to have information about the chromosomal status of the embryo prior to transfer. ”

There are different options for PGT-A. Sometimes laboratories check for only a few chromosomes defects in which can lead to the birth of a child with a chromosomal abnormality. In the Genetico® laboratory, specialists analyze all 46 chromosomes of the embryo using NGS (next generation sequencing).

In this case, the NGS method can «read» the DNA of the embryo a different number of times, which allows testing with different resolution, that is, «see» chromosomal abnormalities of a larger or smaller size. The greater the number of readings, the better chromosomal abnormalities are visible.

At low resolution, only large chromosomal abnormalities are visible. With a higher resolution, even small abnormalities in the embryo’s DNA become visible with good detail. The more information the testing gives, the more objective the information will be for the doctor and family to make a decision about the transfer of certain embryos.

According to various studies, the Embryotest PGT-A increases the effectiveness of IVF from 25-30% to 60-80%. This is because the doctor has an option not to transfer embryos that are unlikely to develop into a normal pregnancy.

Since April 2020, Genetico® Center has been conducting embryo testing for its patients in three versions: High-Resolution Embryotest (1,000,000 reads), Basic Resolution Embryotest (500,000 reads) and Initial Resolution Embryotest (250,000 reads). All testing options are performed on Illumina equipment. Genetico® implements PGT-A in different versions so that patients and the doctor have the opportunity to select the amount of chromosomal studies necessary for a particular patient and not spend extra money.

Genetico® is a research center of the Human Stem Cell Institute (HSCI), accredited by the Skolkovo Foundation as a Shared Use Center (CCC). This is one of the leading laboratory and production complexes in Russia, built in 2013 according to GLP standards. The specialists of Genetico® Center were among the first to have introduced NGS-based embryo testing into healthcare practice.